Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 151, Issue 1, 2010, Pages 72-76

  de la Torre, Javier ^a,b   Sabadell, M Dolors ^a   Rojo, Federico ^a,c   Lirola, Jose Luis ^a   Salicru, Sabina ^a   Reventos, Jaume ^a   Cajal, Santiago Ramón y ^a   Xercavins, Jordi ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Breast; Cyclo oxygenase type 2 (COX 2); Ductal Carcinoma in situ (DCIS); Microinvasive carcinoma of the breast (MICB); Prognosis

Indexed keywords

CYCLOOXYGENASE 2; FORMALDEHYDE; PARAFFIN; POLYCLONAL ANTIBODY; PTGS2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER CELL; CANCER GRADING; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STAINING; TUMOR VOLUME; BREAST TUMOR; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 77953292018     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2010.02.033     Document Type: Article

References (34)

1. Dannenberg A.J., Altorki N.K., Boyle J.O., et al. Cyclooxigenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2 (2001) 544-551
2. Kundu N., Smyth M.J., Samsel L., and Fulton A.M. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat 76 (2002) 57-64
3. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30 (2000) 3-21
4. Sinhg-Ranger G., and Mokbel K. The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. EJSO 28 (2002) 729-737
5. Harris R.E., Alshafie G.A., and Abou-Issa H. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 89 (2000) 2637-2645
6. Kundu N., and Fulton A. Selective Cox-1 or Cox-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62 (2002) 2343-2346
7. Boland G.P., Butt I.S., Prasad R., Knox W.F., and Bundred N.J. Cox-2 Expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90 (2004) 423-429
8. Prasad M., Osborne M., Giri D., and Hoda S. Microinvasive carcinoma (T1mic) of the breast. Am J Pathol 24 3 (2000) 422-428
9. Silverstein M.J., Poller D.N., Waisman J.R., Colburn W.J., Barth A., and Gierson E. Prognostic classification of breast ductal carcinoma in situ. Lancet 345 (1995) 1154-1157
10. Bethwaite P., Smith N., Delahunt B., and Kenwright D. Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast. J Clin Pathol 51 (1998) 450-454
11. Pajak T., Clarkc G.H., sergeant D.J., Mc Shane L.H., and Hammon E.H. Statistical issues in tumor marker studies. Arch Pathol Lab Med 124 (2000) 1011-1015
12. Tyczynski J.E., Bray F., and Parkin D.M. Breast cancer in Europe. ENCR cancer fact sheets vol. 2 (December 2002), International Agency for Research on Cancer
13. Masood S. Prognostic/predictive factors in breast cancer. Clin Lab Med 25 December (4) (2005) 809-825 viii
14. Goldstein N., Kestin L., and Vicini F. Intraductal Carcinoma of the breast. Pathologic features associated with local recurrence in patients treated with Breast-Conserving Therapy. Am J Surg Pathol 24 8 (2000) 1058-1067
15. Munkarah A., and Ali-Fehmi R. COX-2: a protein with an active role in gynaecological cancer. Curr Opin Obstet Gynecol 17 (2005) 49-53
16. Thorat M.A., Mehrotra S., Morimiya A., and Badve S. COX-2 expression does not correlate with microvessel density in breast cancer. Pathobiology 76 1 (2009) 39-44
17. Zerkowski M.P., Camp R.L., Burtness B.A., Rimm D.L., and Chung G.G. Quantitative analysis of breast cancer tissue microarrays shows high COX-2 expression is associated with poor outcome. Cancer Invest 25 January (1) (2007) 19-26
18. RistimaKi A., Sivula A., Lundin M., et al. Prognostic significance of elevated cyclooxigenase-2 expression in breast cancer. Cancer Res 62 (2002) 632-635
19. Denkert C., Winzer K.J., and Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 4 February (6) (2004) 428-433
20. Ristimaki A., Honkanen N., Jankala H., Sipponen P., and Harkoenen M. Expression of cyclooxigenase 2 in human gastric carcinoma. Cancer Res 57 (1997) 1276-1280
21. Wolff H., Saukkonen, Anttila S., Karjalainen A., Vainio H., and Ristimaki A. Expression of cyclooxigenase 2 in human lung carcinoma. Cancer Res 58 (1998) 4997-5001
22. Denkert C., Kobel M., Pest S., et al. Expression of cyclooxigenase 2 is an independent prognostic factors inhuman ovarian carcinoma. Am J Pathol 160 (2002) 893-903
23. Denkert C., Winzer K.J., Müller B.M., et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97 June (12) (2003) 2978-2987
24. Half E., Tang X.M., Gwyn K., Sahin A., Wathen K., and Sinicrope F.A. Cyclooxigenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62 (2002) 1676-1681
25. Kelly L.M., Hill A.D., Kennedy S., et al. Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 29 November (9) (2003) 707-710
26. Gallicchio L., McSorley M.A., Newschaffer C.J., et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106 April (7) (2006) 1443-1452
27. Park K., Han S., Shin E., Kim H.J., and Kim J.Y. Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol 32 December (10) (2006) 1093-1096
28. Ranger G.S., Jewell A., Thomas V., and Mokbel K. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J Surg Oncol 88 November (2) (2004) 100-103
29. O,Connors J.K., Avent J., and Lee R.J. Cyclooxigenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 1034-1040
30. Tan K.B., Yong W.P., and Putti T.C. Cyclooxigenase-2 expression: a potential prognosis and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 44 (2004) 24-28
31. Nassar A., Radhakrishnan A., Cabrero I.A., Cotsonis G., and Cohen C. COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 15 September (3) (2007) 255-259
32. Barnes N.L., Warnberg F., Farnie G., et al. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 96 February (4) (2007) 575-582
33. Leo C., Faber S., Hentschel B., Hockel M., and Horn L.C. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann Diagn Pathol 10 December (6) (2006) 327-332
34. Zhao X., Goswami M., Pokhriyal N., et al. Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res 68 January (2) (2008) 467-475